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Introduction
A variety of drugs and topical agents may cause 
vestibulocochlear toxicity, commonly referred to as 
ototoxicity.1 One of the classes of medication known for 
its ototoxic potential is the aminoglycosides, which can 
damage either the hearing or the vestibular apparatus or 
both. Vestibulotoxicity is the ability of a substance to destroy 
or damage vestibular structures, which could involve the 
end-organ at hair cell level, the vestibular aspect of the 
eighth cranial nerve and connections within the central 
nervous system.2 Aminoglycosides are effective against 
serious enterococcal and Gram-negative infections, low in 
cost and easily accessible, factors that are important when 
clinicians are making choices about medication.3 Thus, 
the clinical problem of adverse outcomes in response to 
medication, in this instance vestibulotoxicity, is an ongoing 
issue that has major relevance for all practitioners who care 
for patients receiving aminoglycosides. 
Aminoglycosides have the ability to target different areas 
of the cochleovestibular system selectively. Of critical 
importance is the fact that vestibulotoxicity can exist 
independently from cochleotoxicity. Gentamicin is the most 
commonly used drug that is administered in a form (i.e. 
parenterally) and dosage that may cause damage, usually 
vestibulotoxicity.4,5 Of particular concern is the widespread 
use of gentamicin in neonates at risk of sepsis, many of 
whom may be premature and have suboptimal renal 
function.6 A small study performed recently suggested 
that damage to the vestibular apparatus does occur in 
infants after as few as three doses of amikacin.7 Other 
aminoglycosides such as streptomycin and kanamycin 
are used predominantly in the treatment of tuberculosis.8-10 
Streptomycin has been found to be primarily vestibulotoxic 
and has a fairly minor cochleotoxic effect.11 It is reasonable 
to assume that in spite of their toxicity, aminoglycosides will 
be used far into the future, as the incidence of tuberculosis 
and multidrug-resistant tuberculosis has been severely 
aggravated by the human immunodeficiency virus/acquired 
immune deficiency syndrome (HIV/AIDS) pandemic.12-15 
The major symptoms of vestibulotoxicity are dizziness, 
dysequilibrium and oscillopsia, as distinct from vertigo, 
which would be a most unusual presentation. The effect 
of vestibulotoxicity is permanent and may affect an 
individual’s quality of life negatively. The development of 
vestibulotoxicity may prolong hospitalisation, necessitate 
intensive vestibular rehabilitation therapy and jeopardise 
the patient’s income, should he or she be unable to drive 
or hold down a job.16 The next section of this review further 
explores the disabling nature of dizziness. 
Disability and quality of life
Dizziness has been shown to cause difficulties in many of 
the activities of daily living, and to impact profoundly on the 
sufferer’s quality of life.17 Impairments that may result from 
disorders of the vestibular system include gaze instability, 
altered perception of motion and orientation in space and 
the inappropriate use of balance strategies, which develop 
during the compensatory stage.18 Specifically, issues that 
may result from bilateral vestibular hypofunction, often 
as the result of vestibulotoxicity, include oscillopsia, gait 
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ataxia, nausea, light-headedness, veering when walking 
and an increased risk of falling.19 Because of these 
symptoms, patients should be advised to avoid heights, 
operating machinery and driving until they are assessed 
as able to do so with safety.20 For vestibulotoxic patients 
with a guarded prognosis for recovery, the ramifications of 
these restrictions would obviously depend on the patient’s 
occupation. However, the magnitude of disability caused 
by vestibulotoxicity should not be underestimated. In one 
study, all of 33 participants were disabled after gentamicin 
vestibulotoxicity.21 None of the individuals resumed their 
premorbid occupations, and 32 became dependent on 
disability and social grants. 
In addition to the physical limitations imposed on 
vestibulotoxic patients, there are other effects. Magnetic 
resonance imaging evidence has suggested that the 
hippocampus may atrophy in cases of bilateral vestibular 
hypofunction ,and that this could be linked to a range of 
cognitive deficits. Vestibular damage in the hippocampus 
could also be the cause of emotional changes that result 
in anxiety and depression.22 Psychological distress 
and disability in participants with vertigo (including 
vestibulotoxicity) is greater than expected, with anxiety and 
depressed affect.23 Another study highlighted that the most 
troubling handicaps of vestibular hypofunction were social 
and physical restrictions of activities, worry and a lack of 
confidence.17 Importantly, these feelings of not being able to 
cope may lead to activity restriction, which in turn reduces 
the chance of any recovery. Considering the permanent 
damage that occurs in vestibulotoxicity, also noteworthy 
was the link between the length of time that patients had 
lived with their illness and the levels of somatic anxiety, 
disease-specific handicap and decreased psycho-social 
functioning.17 While vestibulotoxicity was not addressed 
specifically, it can be argued that the limited response to 
therapy and the permanent nature of vestibulotoxicity 
would cause even more profound disability. Hence, 
vestibulotoxicity triggers a combination of physical and 
psychological symptoms that result in a deterioration in the 
quality of life, and even in the earning potential. 
Factors influencing occurrence 
Differences in study design and methodologies have 
resulted in variable and controversial data regarding the 
incidence of vestibulotoxicity.8,24,25 Many of the reports have 
small numbers of participants and thus lack generalisability. 
Risk factors for the development of vestibulotoxicity may 
be broadly summarised under three main considerations: 
drug variables, patient variables and the awareness of the 
attending clinician.26 
Drug variables
Early research suggested that 3–5% of patients treated 
with streptomycin would become vestibulotoxic, while later 
research suggested that this figure could be as high as 
10%.27,28 Gentamicin was found to be vestibulotoxic in two-
thirds of patients who received it.29 
Apart from the choice of drug, additional factors that may 
influence vestibulotoxicity are dosage issues, in terms 
of quantity and frequency, and duration of treatment. 
Commonly employed treatment protocols for tuberculosis 
suggest that dosages of aminoglycosides may be 
calculated according to categories of body mass (e.g. 50– 
75 kg).15 Animal studies have suggested that ototoxicity was 
more marked when the animals were nutritionally deprived.30 
Thus, it is possible that patients at the lower range of such 
a broad weight band would be at higher risk. Some authors 
recommend a once-a-day dosage rather than splitting the 
dosage into two per day;31 however, only a few studies with 
a limited number of participants have examined the link 
between once-daily administration and vestibulotoxicity.16 
Whilst it would be obvious that continuous exposure would 
increase the risk, it should be noted that aminoglycosides 
can be vestibulotoxic within short treatment periods.7
Patient variables
In the diagnosis of the majority of vestibular disorders, it 
is generally agreed that the quality of history taking is of 
critical importance. It would seem obvious to ask patients 
about the onset or aggravation of symptoms such as 
hearing loss, tinnitus, nausea or dysequilibrium. However, 
symptom description cannot reliably be used to identify 
or track vestibulotoxicity for a variety of reasons.32 First, 
patients with severe vestibulotoxicity suffer from slowly 
progressive bilateral vestibular hypofunction and so 
the presenting complaint is most unlikely to be acute, 
severe vertigo.32 Perpetual dizziness, dysequilibrium, 
ataxia and oscillopsia, rather than vertigo, are the typical 
presentation of vestibulotoxicity.16,32,33 These symptoms are 
only apparent when patients are mobilised and are often 
incorrectly attributed to the patient’s debilitated state.33,34  
Second, patients may use various terms for the symptom of 
dizziness, ranging from “weak” and “sick”, to “giddy” and 
“spinning”.35 Some of these words may not alert staff to the 
possibility of vestibular dysfunction. Third, in a multilingual 
setting such as South Africa, there may not be words 
in indigenous languages to describe the symptoms of 
vestibulotoxicity adequately. Attending staff with linguistic 
backgrounds that differ from those of their patients may 
easily misinterpret nebulous symptom reports that would 
otherwise alert them to vestibulotoxicity.
Risk factors for cochleotoxicity include genetic susceptibility, 
renal impairment, hyperthermia, dosage in relation to weight, 
concomitant treatment with other oto- or nephrotoxic 
medication, prior or prolonged exposure to ototoxic 
medication, pre-existing dysfunction, advanced age and 
poor nutrition.26,36 However, there are little data to support 
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Healthcare practitioner variables 
In the moribund patient the primary consideration is, 
understandably, saving the individual’s life. Thus, the use 
of aminoglycosides could be argued to justify the risk of 
adverse drug effects, and this will heavily influence decision 
making. In cases where aminoglycosides are given, the 
clinician’s knowledge concerning vestibulotoxicity will 
have an impact on the accuracy and speed of diagnosis 
and the prognosis.26 As the symptoms of dysequilibrium 
and oscillopsia may not be obvious, especially if the 
patient is bedridden, they may be overlooked. One study 
suggested that most patients with permanent gentamicin 
vestibulotoxicity were not diagnosed prior to discharge from 
hospital.21 Patients complained of symptoms only to have 
them ignored or incorrectly treated, suggesting that doctors’ 
knowledge of vestibulotoxicity is not adequate.33 It would 
be extremely unusual for patients with vestibulotoxicity to 
display the sign of nystagmus or symptoms of vertigo.26 
Thus, it is disappointing to note that in publications such as 
the World Health Organization’s Treatment of Tuberculosis 
Guidelines for National Programmes,15 nystagmus 
and vertigo are listed under adverse drug effects for 
aminoglycosides; events that are most unlikely to occur 
given the mechanism of bilateral vestibular failure. This in 
turn could lead to missed diagnoses among practitioners 
expecting to see these signs. 
Clinicians may be unaware that vestibulotoxicity can occur 
without cochlear hearing loss.37 There is no correlation 
between serum or plasma levels and vestibulotoxicity; 
vestibulotoxicity may still occur in spite of measured 
“non-toxic” levels of the drugs.10,21,36 Both these examples 
demonstrate how the knowledge of the clinician may impact 
on patient management. 
In addition to awareness of vestibulotoxicity, the attitude 
of the staff attending to patients undergoing treatment with 
aminoglycosides may have an impact on the likelihood 
of symptoms being reported, and even on a decision to 
investigate these symptoms. Research into attitudes of 
nurses in South Africa caring for patients with tuberculosis 
suggested that nurses could be authoritarian, scolding and 
frustrated.38 This could result in the patients’ unwillingness 
to raise complaints. 
Diagnosis
The effect of ototoxic drugs on vestibular function is not 
always clear.39 Several issues compound the diagnosis 
of vestibulotoxicity. Methods available to evaluate 
vestibulotoxicity are not always sensitive enough to 
demonstrate the subtle changes that could uphold the 
diagnostic symptoms.39 For example, it was postulated 
that a reduction of 20–40% in hair cells may be necessary 
before canal paresis will be evident on caloric testing.40 In 
addition, behavioural and reflex tests are frequently unable 
to differentiate between peripheral and central vestibular 
damage,39 making precise site-of-lesion diagnosis difficult, 
which could in turn affect vestibular rehabilitation therapy 
decisions. Finally, vestibular assessment is extremely 
challenging in ill patients.8 
Testing options range from bedside examinations to 
sophisticated specialised testing. Both can be used for 
either diagnostic or monitoring purposes. 
Bedside examination
Bedside testing can yield important diagnostic information. 
The expected results of bedside tests that would be 
associated with vestibulotoxicity are shown in Table I.
Special investigations of vestibular function
Tests that utilise specialised equipment can quantify 
vestibular function, but are not diagnostic in themselves.42 
While the literature offers reports of the sensitivity and 
specificity of various tests of vestibular function, which are 
summarised in Table II, it should be stressed that these 
tests are time consuming and difficult to administer to 
patients who are acutely ill or moribund. Furthermore, a 
battery of tests, all dependent on different and expensive 
pieces of equipment, may be required to build an overall 
picture of a patient’s balance and postural control. Finally, 
the equipment is usually only found in specialised facilities 
and the personnel required generally have to be specially 
trained, experienced and competent individuals. 
Treatment
Spontaneous recovery from vestibulotoxicity
Reports concerning the level of recovery of vestibular 
function in cases of bilateral vestibular hypofunction are 
sparse and reflect contradictory results. It was noted that 
regeneration of receptor cells damaged by gentamicin 
was possible.49 However, in a study by the same authors, 
which examined functional recovery of balance, there 
was no improvement in a large majority (80%) of chronic 
cases of vestibulotoxicity. It should also be noted that 
vestibulotoxicity may continue to progress, even once the 
drug has been withdrawn.21,32 
Pharmacology 
The use of medication in treating dizziness and vertigo is 
challenging and does not always yield optimal results.50 
A balance must be struck between symptom control and 
undesired side-effects, such as sedation and delay in or 
prevention of compensatory processes.51 In general, drugs 
that are known to reduce the symptoms of certain forms 
of otological vertigo (such as vestibular suppressants) have 
been described as aggravating the symptoms of bilateral 
vestibular hypofunction.50 Because of the issues concerning 
the quality of life of those who have vestibulotoxic 
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Table I: Bedside tests of vestibular function, and results if the patient has bilateral vestibular hypofunction (adapted from Black and Pesznecker41)
Test Aim of evaluation Results if vestibulotoxic Notes
Inspection for 
nystagmus
Establish presence and grade of 
spontaneous and/or gaze nystagmus.
No nystagmus will be evident as loss of 
aVOR input is usually symmetrical.
Requires experienced clinician.
Reliability enhanced if Frenzel lenses are 
used. 
Head thrust test Establish if VOR input is present and 
normal.
Will have saccades in both directions. Need appropriate training.
Should be a routine test.
Sensitivity of 84–100% if bilateral 
vestibular hypofunction. 
Dynamic visual acuity 
test
Establish if patient has early oscillopsia. Will have decline in vision when head is 
moving.
Snellen chart or similar required.
Should be a routine test. 




Attempts to be more of a test of vestibular 
function by reduction of proprioceptive 
cues.
Cannot assume position when acute. May be possible with eyes open if 
compensated, not with eyes closed.
Gait Identify ataxia and gait abnormalities. Wide based, slow, may need assistance 
when acute.
Even when compensated may have a 
shortened step length.
Falls and fall risk Patient at great risk of falling. Remains greater in all age groups even 
when compensated. 
May need assistive device or may result in 
decreased activities.
Bedside caloric test Establish function of lateral semicircular 
canal.
Reduced response bilaterally. Reliability enhanced if clinician is 
experienced. 
Better results obtained if headlight and 
Frenzel lenses are used. 
Patients with no or reduced response 
should be referred for formal testing.
Crude test, does not test whole system.
a= Vestibulo-ocular reflex
Table II: Sensitivity and specificity of laboratory investigations to establish the presence of peripheral vestibulopathy. All tests can be performed over time and 
thus there is a potential for monitoring.
Test Aim of evaluation Advantages Disadvantages Sensitivity Specificity




Widely used, established technique.
Evaluates in eyes-closed condition, which 
is preferable for peripheral vestibular 
nystagmus.
Calorics: evaluates each ear separately.
Reasonable consensus as to what is 
abnormal.
Reflects permanent deficits.
Lack of standardised norms, especially in 
elderly populations. 
Calorics: very slow stimulus; wide variability 
in strength of stimulus; only lateral 
semicircular canal tested.





cROTO42,45-48 As above Very useful to establish bilateral loss (”gold 
standard”).
Can determine whether reduced caloric 
responses are due to inadequate stimulation 
or true vestibular loss.
Can assist with therapeutic decisions.
May demonstrate residual function in the 
absence of caloric responses on ENG.
Reflects dynamic compensation.
No selective targeting of each ear.
Little consensus on abnormality.
Not widely available.
May miss unilateral or asymmetrical 
dysfunction.
No standardisation regarding stimulus and 
analysis techniques.
71% 54%
Posturography46,48 Evaluates relative 
contribution of 
sensory and motor 
components of 
balance. 
Assesses abnormal patterns of postural 
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While drugs, such as one of the selective serotonin reuptake 
inhibitors, may be indicated, it is suggested that these be 
used sparingly, as they are associated with side-effects of 
increased tinnitus, increased risk of falling and nausea.50 
Vestibular rehabilitation therapy
Vestibular rehabilitation therapy (VRT) has been a major 
step forward in the management of dizzy and vertiginous 
patients. This is especially important as medication is often 
unhelpful,50 leaving VRT as the treatment of choice for 
particular disorders of balance and gait. 
VRT is currently the only suitable treatment option for patients 
with vestibulotoxicity, but results are variable and sometimes 
disappointing. While not specific to vestibulotoxicity, there 
is some evidence that VRT introduced as soon as possible 
after the insult may result in a good outcome.52 The aims 
of VRT for vestibulotoxic patients are as follows: to ensure 
safety when moving, to prevent further deconditioning due 
to fear of falling and activity avoidance, and environmental 
and lifestyle management.20 Although some improvement 
may be experienced, patients continue to be at risk of falling 
and report significant perceived physical impairment and 
disability.19 Gillespie and Minor53 cite studies in which up 
to 50% of patients failed to respond to VRT. Patients with 
medical co-morbidities have a poorer prognosis for recovery 
than those without, probably due to deconditioning, which 
would prevent full participation in a VRT programme.53,54 
However, age does not seem to be a significant obstacle 
to recovery.52 
Monitoring 
As referred to earlier, there appears to be a lack of association 
between aminoglycoside dose or serum concentration and 
vestibulotoxicity, so even if levels are normal, damage may 
still occur. Furthermore, there is no single test that can 
predict or identify the presence of vestibulotoxicity, and as 
can be seen from Table II, the sensitivity and specificity of 
the available tests are suboptimal. Vasquez and Mattucci55 
recommend a flexible approach when monitoring patients 
for the effects of ototoxicity and suggest that even if bedside 
testing such as dynamic visual acuity and head thrust is the 
only method available to monitor patients, this is preferable 
to no monitoring at all, a view supported by others.3,4,16,56 It 
should be noted that monitoring should continue after the 
drug has been withdrawn, as, in many cases, symptoms 
first appear after discharge. Figure 1 presents an idealised 
scheme of the professionals and services that could be 
involved in the holistic care of the patient undergoing 
treatment with aminoglycosides. 
Conclusion
The continued use of aminoglycosides has stimulated a 
desire to understand the mechanism of ototoxicity and to 
develop strategies to reduce the ototoxic potential of these 
drugs.57 While the usual rationale for the administration of 
aminoglycosides is to save the life of a seriously ill patient, it 
has been suggested that patients and their families may not 
always be advised of the ototoxic potential of these drugs.21 
It is possible that this is due to a lack of awareness on the 
part of the prescribing clinician, which is then compounded 
by a lack of awareness of symptoms of ototoxicity during 
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the course of treatment. Although alternative drugs are 
available, cost and other factors may still influence choices. 
In view of the permanent and extremely disabling effects 
of aminoglycosides and their continued common use, this 
debate needs to be moved into the everyday clinical arena 
as a matter of urgency. 
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